SCHEMBL623910

SCHEMBL623910

O=C(c1ccccc1-c1cc[nH]n1)N1CCN(c2cc(OCC(F)(F)F)ncn2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
CYP2C19 P33261 3/20 0.40
CYP1A2 P05177 2/20 0.40
SLC6A7 Q99884 1/20 0.39
RAB9A P51151 1/20 0.39
ACACB O00763 1/20 0.38
GBA1 P04062 1/20 0.37
SCD O00767 2/20 0.37
HTT P42858 1/20 0.36
ITGB2 P05107 1/20 0.36
ICAM1 P05362 1/20 0.36
ITGAL P20701 1/20 0.36
HCRTR2 O43614 1/20 0.36
CYP2C9 P11712 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PARP1 P09874 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL624147 0.79 MAPK14 (0.48) LMNAKDM4ESMN1; SMN2RAB9AACACB
SCHEMBL624545 0.76 RBP4 (0.49) LMNAALDH1A1TSHRHTT
SCHEMBL623199 0.76 GAA (0.46) ALDH1A1KDM4ECYP2C19CYP1A2RAB9A
SCHEMBL624261 0.74 ALDH1A1 (0.46) LMNAALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL623245 0.74 TSHR (0.53) ALDH1A1TSHRKDM4ESMN1; SMN2RAB9A
SCHEMBL623899 0.74 PTK2 (0.51) LMNAALDH1A1KDM4ESMN1; SMN2RAB9A
SCHEMBL623227 0.73 HSD17B10 (0.45) SMN1; SMN2CYP2C19CYP1A2RAB9AACACB
SCHEMBL623662 0.73 SMN1; SMN2 (0.63) LMNAALDH1A1TSHRKDM4ESMN1; SMN2
SCHEMBL623073 0.73 HSD17B10 (0.44) SMN1; SMN2ACACBHSD17B10
SCHEMBL624639 0.72 DRD2 (0.51) LMNAALDH1A1TSHRKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G LMNA 2282/4885ALDH1A1 2071/4885TSHR 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.